44.46
Mirum Pharmaceuticals Inc stock is traded at $44.46, with a volume of 336.38K.
It is up +1.05% in the last 24 hours and up +4.51% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$44.00
Open:
$43.85
24h Volume:
336.38K
Relative Volume:
0.76
Market Cap:
$2.20B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-27.58
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+1.05%
1M Performance:
+4.51%
6M Performance:
-3.81%
1Y Performance:
+81.91%
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MIRM
Mirum Pharmaceuticals Inc
|
44.46 | 2.18B | 379.25M | -77.34M | -27.87M | -1.6122 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-19-25 | Resumed | H.C. Wainwright | Buy |
Apr-17-24 | Initiated | Stifel | Buy |
Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Nov-13-23 | Initiated | Morgan Stanley | Overweight |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-17-23 | Resumed | Evercore ISI | Outperform |
Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-01-22 | Initiated | Citigroup | Buy |
Sep-20-21 | Initiated | JP Morgan | Overweight |
Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
Aug-03-20 | Initiated | H.C. Wainwright | Buy |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
Jun-25-20 | Initiated | Robert W. Baird | Outperform |
Aug-12-19 | Initiated | Citigroup | Buy |
Aug-12-19 | Initiated | Evercore ISI | Outperform |
Aug-12-19 | Initiated | Guggenheim | Buy |
Aug-12-19 | Initiated | ROTH Capital | Buy |
Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Alagille Syndrome Treatment Market Detailed in New Research ReportMirum Pharmaceuticals, Albireo Pharma - openPR.com
Two Sigma Investments LP Has $5.23 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Man Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential - Investing.com Nigeria
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
When the Price of (MIRM) Talks, People Listen - news.stocktradersdaily.com
Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes - Defense World
What is HC Wainwright’s Estimate for MIRM Q2 Earnings? - Defense World
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - citybiz
Comerica Bank Reduces Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Given “Buy” Rating at HC Wainwright - Defense World
Mirum Pharmaceuticals Names Doug Sheehy New Chief Legal Officer - Bloomberg Law News
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwri - GuruFocus
Mirum Pharmaceuticals (MIRM) Appoints New Chief Legal Officer | - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwright & Co. | MIRM Stock News - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating with Promising Growth Potential | MIRM Stock News - GuruFocus
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $60.64 - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - MSN
Northern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
FY2025 EPS Estimates for MIRM Raised by Cantor Fitzgerald - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for MIRM - Defense World
JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $76.00 - Defense World
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JMP raises Mirum Pharmaceuticals stock target to $76 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Nigeria
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Revenue $111.6M, vs. FactSet Est of $98.4M - marketscreener.com
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):